Longeveron (LGVN) Change in Intangibles (2020 - 2026)
Longeveron (LGVN) recorded quarterly Change in Intangibles of $20000.0 in Q1 2026, down 68.75% quarter-over-quarter from $64000.0 in Q4 2025, and down 83.74% on a YoY basis from $123000.0 in Q1 2025.
Longeveron (LGVN) Change in Intangibles (2020 - 2026) Analysis & Trends
Longeveron's Change in Intangibles history runs 7 years deep, the most recent figure standing at $20000.0 for Q1 2026.
- In Q1 2026, Change in Intangibles fell 83.74% year-over-year to $20000.0; the TTM figure through Mar 2026 stood at $247000.0 (down 42.42% YoY), while the FY2025 annual figure was $350000.0, up 3.86% from the prior year.
- Change in Intangibles was $20000.0 for Q1 2026 at Longeveron, down from $64000.0 in the prior quarter.
- In the past five years, Change in Intangibles ranged from a high of $146000.0 in Q2 2024 to a low of $19000.0 in Q2 2022.
- Historically, Change in Intangibles has averaged $81588.2 across 5 years, with a median of $92000.0 in 2022.
- Biggest YoY gain for Change in Intangibles was 600.0% in 2022; the steepest drop was 89.06% in 2022.
- A 5-year view of Change in Intangibles shows it stood at $92000.0 in 2022, then grew by 3.26% to $95000.0 in 2023, then advanced by 15.79% to $110000.0 in 2024, then tumbled by 41.82% to $64000.0 in 2025, then plunged by 68.75% to $20000.0 in 2026.
- The last three Change in Intangibles figures came in at $20000.0 (Q1 2026), $64000.0 (Q4 2025), and $61000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.96 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20,000.00 |
| Mar 31, 2026 | 20,000.00 |
| Dec 31, 2025 | 64,000.00 |
| Dec 31, 2025 | 64,000.00 |
| Sep 30, 2025 | 61,000.00 |
| Sep 30, 2025 | 61,000.00 |
| Jun 30, 2025 | 102,000.00 |
| Jun 30, 2025 | 102,000.00 |
| Mar 31, 2025 | 123,000.00 |
| Mar 31, 2025 | 123,000.00 |
| Dec 31, 2024 | 110,000.00 |
| Dec 31, 2024 | 110,000.00 |
| Sep 30, 2024 | 50,000.00 |
| Sep 30, 2024 | 50,000.00 |
| Jun 30, 2024 | 146,000.00 |
| Jun 30, 2024 | 146,000.00 |
| Mar 31, 2024 | 31,000.00 |
| Mar 31, 2024 | 31,000.00 |
| Dec 31, 2023 | 95,000.00 |
| Dec 31, 2023 | 95,000.00 |